Kodiak Sciences Inc (FRA:K27)
€ 3.546 0.072 (2.07%) Market Cap: 211.94 Mil Enterprise Value: 80.00 Mil PE Ratio: 0 PB Ratio: 0.96 GF Score: 37/100

Kodiak Sciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 07:50PM GMT
Release Date Price: €125 (+5.04%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome everyone to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Matt Bannon and Tessa Romero from the team. Our next presenting company is Kodiak Sciences, and speaking on behalf of the company, we have CEO, Victor Perlroth.

Before I turn it to Victor, I just wanted to highlight for those listening on the webcast, you can submit a question by the Ask a Question feature in the portal, and I recommend everyone to do that. Victor?

Victor Perlroth
Kodiak Sciences Inc. - Chairman, MD, CEO & President

Hi, Anupam. Thank you. It's my pleasure to be here at the conference to present Kodiak as a company, our lead product, KSI-301 and its accelerating development plan and our ABC Platform with the deepening pipeline of medicines focused for retina diseases. Yes. I think we'll move forward with about a 15- or 20-minute presentation, and then we'll save time for questions.

Let's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot